Literature DB >> 21146524

Heterophilic chemokine receptor interactions in chemokine signaling and biology.

Birgit K Kramp1, Alisina Sarabi, Rory R Koenen, Christian Weber.   

Abstract

It is generally accepted that G-protein coupled receptors (GPCR), like chemokine receptors, form dimers or higher order oligomers. Such homo- and heterophilic interactions have been identified not only among and between chemokine receptors of CC- or CXC-subfamilies, but also between chemokine receptors and other classes of GPCR, like the opioid receptors. Oligomerization affects different aspects of receptor physiology, like ligand affinity, signal transduction and the mode of internalization, in turn influencing physiologic processes such as cell activation and migration. As particular chemokine receptor pairs exert specific modulating effects on their individual functions, they might play particular roles in various disease types, such as cancer. Hence, chemokine receptor heteromers might represent attractive therapeutic targets. This review highlights the state-of-the-art knowledge on the technical and functional aspects of chemokine receptor multimerization in chemokine signaling and biology.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21146524     DOI: 10.1016/j.yexcr.2010.11.014

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  19 in total

1.  The yin and yang of chemokine receptor activation.

Authors:  Graeme O'Boyle
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 2.  Allosteric function and dysfunction of the prion protein.

Authors:  Rafael Linden; Yraima Cordeiro; Luis Mauricio T R Lima
Journal:  Cell Mol Life Sci       Date:  2011-10-09       Impact factor: 9.261

Review 3.  CXCL12 signaling in the development of the nervous system.

Authors:  Divakar S Mithal; Ghazal Banisadr; Richard J Miller
Journal:  J Neuroimmune Pharmacol       Date:  2012-01-21       Impact factor: 4.147

Review 4.  Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.

Authors:  Christopher Kent Arnatt; Yan Zhang
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

5.  Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation.

Authors:  Graeme O'Boyle; Christopher R J Fox; Hannah R Walden; Joseph D P Willet; Emily R Mavin; Dominic W Hine; Jeremy M Palmer; Catriona E Barker; Christopher A Lamb; Simi Ali; John A Kirby
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-05       Impact factor: 11.205

Review 6.  Chemokines and BPH/LUTS.

Authors:  Jill A Macoska
Journal:  Differentiation       Date:  2011-05-19       Impact factor: 3.880

7.  A novel approach to quantify G-protein-coupled receptor dimerization equilibrium using bioluminescence resonance energy transfer.

Authors:  Irina Kufareva; Bryan Stephens; C Taylor Gilliland; Beili Wu; Gustavo Fenalti; Damon Hamel; Raymond C Stevens; Ruben Abagyan; Tracy M Handel
Journal:  Methods Mol Biol       Date:  2013

8.  Differential roles of CXCL2 and CXCL3 and their receptors in regulating normal and asthmatic airway smooth muscle cell migration.

Authors:  Laila A Al-Alwan; Ying Chang; Andrea Mogas; Andrew J Halayko; Carolyn J Baglole; James G Martin; Simon Rousseau; David H Eidelman; Qutayba Hamid
Journal:  J Immunol       Date:  2013-07-31       Impact factor: 5.422

9.  Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: molecular modeling and experimental validation.

Authors:  Irina Kufareva; Bryan S Stephens; Lauren G Holden; Ling Qin; Chunxia Zhao; Tetsuya Kawamura; Ruben Abagyan; Tracy M Handel
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-02       Impact factor: 11.205

Review 10.  Chemokine oligomerization in cell signaling and migration.

Authors:  Xu Wang; Joshua S Sharp; Tracy M Handel; James H Prestegard
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.